Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 12:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Renal Function Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment

NCT02402452
View directory record Official record
Conditions
HCV Infection
Interventions
Voxilaprevir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Jun 27, 2026, 12:05 AM EDT
Completed Phase 1 Interventional

A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

NCT01904214
View directory record Official record
Conditions
Renal Impairment
Interventions
BAF312
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Jun 27, 2026, 12:05 AM EDT
Completed Phase 2 Interventional

Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

NCT00159614
View directory record Official record
Conditions
Heart Failure, Congestive, Renal Insufficiency
Interventions
KW-3902IV
Drug
Lead sponsor
NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
6
States / cities
San Diego, California • Baltimore, Maryland • Ayer, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2008 · Synced Jun 27, 2026, 12:05 AM EDT
Completed Phase 4 Interventional

Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation

NCT00425126
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Epoetin Alfa
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2010 · Synced Jun 27, 2026, 12:05 AM EDT
Active, not recruiting No phase listed Observational

MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus

NCT03945747
View directory record Official record
Conditions
Type1 Diabetes Mellitus, Diabetes Mellitus, Type 1, Autoimmune Diabetes, Juvenile Diabetes, Diabetes Mellitus Complication, Diabetic Nephropathies, Metabolic Disease, Diabetic Kidney Disease
Interventions
Blood draw, Urine sample collection, DXA scan
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
7 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Jun 27, 2026, 12:05 AM EDT
Active, not recruiting Phase 4 Interventional

Nitrite-boosting Therapy for Improving Physiological Function in Patients With Chronic Kidney Disease

NCT03826147
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Nitrate-rich beetroot juice, Nitrate-depleted beetroot juice
Dietary Supplement
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
30 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jun 27, 2026, 12:05 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function

NCT00568009
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
SLV320
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
10
States / cities
Whittier, California • Largo, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2008 · Synced Jun 27, 2026, 12:05 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants

NCT05525507
View directory record Official record
Conditions
End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions
Conditioning and Stem cell infusion
Combination Product
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jun 27, 2026, 12:05 AM EDT
Withdrawn Phase 4 Interventional

Combination Diuretic Therapy for Acute Decompensated Heart Failure

NCT05840536
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Furosemide plus Chlorothiazide, Furosemide
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Jun 27, 2026, 12:05 AM EDT
Active, not recruiting No phase listed Observational

A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD

NCT05193981
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
15 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jun 27, 2026, 12:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Aldafermin (NGM282) in Participants With Impaired Renal Function

NCT04179630
View directory record Official record
Conditions
Impaired Renal Function
Interventions
Aldafermin (NGM282)
Biological
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Jun 27, 2026, 12:05 AM EDT
Completed Phase 1 Interventional Results available

Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab

NCT02275156
View directory record Official record
Conditions
Hyperlipidemia, Mixed Dyslipidemia
Interventions
Evolocumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 6, 2022 · Synced Jun 27, 2026, 12:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

NCT05624710
View directory record Official record
Conditions
Renal Insufficiency, Kidney Diseases
Interventions
INCB054707
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Tustin, California • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Jun 27, 2026, 12:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer

NCT02646358
View directory record Official record
Conditions
Pharmacokinetics of Vepoloxamer, Healthy Volunteers, Renal Impaired
Interventions
Vepoloxamer
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
2
States / cities
Lakewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Jun 27, 2026, 12:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis

NCT06723535
View directory record Official record
Conditions
Kidney Failure, Chronic, Healthy Volunteers, Renal Impairment
Interventions
BMS-986278
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 84 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jun 27, 2026, 12:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function

NCT02441829
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Eleclazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
5
States / cities
DeLand, Florida • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Jun 27, 2026, 12:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment

NCT05865171
View directory record Official record
Conditions
Renal Impairment
Interventions
IXP
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Ocala, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Jun 27, 2026, 12:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

NCT04752293
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction, Left Atrial Dilatation, Left Ventricular Diastolic Dysfunction, Kidney Diseases, Kidney Injury, Kidney Dysfunction, Sodium Urine High, Blood Pressure Disorders, Uric Acid Retention, Angiotensin Hypertension, Autonomic Dysfunction, Autonomic Imbalance, Pediatric Kidney Disease, Pediatric Obesity, Proteinuria, Albuminuria
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
7 Years to 18 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jun 27, 2026, 12:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function

NCT02442258
View directory record Official record
Conditions
Renal Impairment
Interventions
ABT-493, ABT-530
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Jun 27, 2026, 12:05 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function

NCT03001817
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
K-877, Fenofibrate, Placebo (for K-877), Placebo (for Fenofibrate)
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
110
States / cities
Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 94 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Jun 27, 2026, 12:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function

NCT01759576
View directory record Official record
Conditions
Renal Insufficiency, Healthy
Interventions
Canagliflozin (JNJ-28431754)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 28, 2013 · Synced Jun 27, 2026, 12:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

NCT02134314
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
Interventions
C1 Esterase Inhibitor, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2018 · Synced Jun 27, 2026, 12:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function

NCT01716455
View directory record Official record
Conditions
Impaired Renal Function
Interventions
SSP-004184
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 85 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Jun 27, 2026, 12:05 AM EDT
Completed Not applicable Interventional

Assessing Novel Methods of Improving Patient Education of Nutrition

NCT00394576
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Internet-based nutrition module along with usual care, usual care
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 5, 2019 · Synced Jun 27, 2026, 12:05 AM EDT